SUPN
NASDAQ
$47.42
Supernus Pharmaceuticals Inc (SUPN)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Sector:
Healthcare
Buy
Target: $63.50 (+33.91%)
Market Cap
$2.77B
Free Cash Flow Yield
2.97%
Beta (5Y)
0.48
Price Chart
Valuation
Market Cap$2.77B
Forward P/E20.16
PEG1.47
P/S3.60
P/B2.57
Profitability
Total Revenue (TTM)$777M
Gross Profit (TTM)$576M
EBITDA$37M
Profit Margin-1.1%
Operating Margin-4%
EPS-$0.50
Financial Health
Free Cash Flow Yield2.97%
Growth & Risk
Revenue 5Y CAGR+6.90%
FCF 5Y CAGR-12.81%
Beta (5Y)0.48
Sharpe Ratio1.02